KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-16
Target enrollment:
Participant gender:
Summary
This is a study aimed at testing a commonly available and inexpensive chemical (hydrogen
peroxide) for efficacy in sensitising large cancerous lumps in the breast to a standard
course of radiotherapy in patients with locally advanced or recurrent breast cancer.
Laboratory research and initial clinical trials in Japan suggest that 4 to 6 injections of a
radiation sensitiser ('KORTUC') based on very dilute (0.5%) hydrogen peroxide injected into
cancers under local anaesthetic twice a week during radiotherapy greatly increases the
effectiveness of standard doses of radiotherapy alone. The side effects are limited to
mild/moderate discomfort at the injection site for up to 24 hours reported by Japanese breast
cancer patients in whom this treatment has been tested. Complete tumour shrinkage in 70/71
(98%) primary breast cancers up to 5 cm diameter have been reported by Japanese
collaborators.